“You should go home, Arjun,” she said, leaning against the doorframe. “The third dissolution trial failed again.”
“You want me to pitch ‘beeswax and fruit gum’ to the board?” Arjun asked, a tired smile playing on his lips. veriton pharma limited
He rubbed his eyes. Two percent. That was the razor’s edge between a breakthrough generic for a life-saving anti-coagulant and complete failure. For six months, the R&D team had been stuck. Millions of rupees had evaporated into solvents, binders, and failed crystallization processes. The board was losing patience. His predecessor had resigned over this very molecule. “You should go home, Arjun,” she said, leaning
The hearing was held in a stuffy conference room in Delhi. The regulator, an old-school pharmacologist named Dr. Sharma, listened to both sides. The rival’s lawyers cited reams of EU regulations. Arjun’s lawyer stammered about tradition and bioequivalence. Two percent
For the next 72 hours, Veriton Pharma’s usually sterile R&D lab looked like a medieval apothecary. They sourced pharmaceutical-grade beeswax. They synthesized a purified analog of the kodampuli polysaccharide. The junior chemists thought Arjun had lost his mind. The head of quality assurance threatened to resign.
Arjun knew it wasn’t about safety. It was about a patent. The rival had a synthetic polymer coating under patent. Veriton’s beeswax-and-gum solution circumvented it, threatening their monopoly.